An ongoing trial (NCT04053283) is assessing a tumor-selective vector expressing a FAP-T cell activator bispecific antibody, which also expresses CXCL9, CXCL10, and IFN-a in multiple epithelial cancers, and preliminary data showed no toxicity [139]. This evidence concerns the gene CXCL10 and neoplasm.